TTOO t2biosystems.com: Forward P/S Multiple

T2 Biosystems, Inc. (TTOO) leads the rapid pathogen diagnostics market thanks to its life-saving T2MR technology. The projected P/S dynamics illustrate the market response to this success. Meanwhile, revenue growth is driven by system implementation in clinics and FDA approval, while diversified electronics suppliers ensure supply chain stability. The value of 0.50 indicates the current level of this ratio.

t2biosystems.com - TTOO Market Cap to Expected Sales Ratio (period 07/04/2022 - 02/22/2025)

Metric breakdowns and analytics for T2 Biosystems Inc (TTOO)

- current price and projected stock value:

Stock Price T2 Biosystems|TTOO - Average Forecast Price

- company stock capitalization data:

Market Capitalization T2 Biosystems Inc|TTOO - Business Value

- issuer book value statistics:

Book Value per Share T2 Biosystems|TTOO - Book Valuation of Business|Market Capitalization to Book Value Ratio t2biosystems.com|TTOO - Cumulative Company Assets

- company total debt and liquidity indicators:

- financial results and valuation multiples details:

TTOO - Annual Net Income|Future Profit T2 Biosystems, Inc.|TTOO - P/E Multiple|Forward P/E Multiple T2 Biosystems, Inc|TTOO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization T2 Biosystems Inc|TTOO - Profit before deduction of interest, taxes, depreciation and amortization|Earnings per share for the last twelve months T2 Biosystems|TTOO - Net earnings per share for the last 12 months|Quarterly EPS earnings growth t2biosystems.com|TTOO - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year T2 Biosystems, Inc.

- sales volume and revenue indicators:

TTOO - Company Sales Volume|Company Future Sales Volume T2 Biosystems|TTOO - Market Cap to Sales Volume|Forward Price-to-Revenue Multiple T2 Biosystems Inc

Summary company analytics:T2 Biosystems (TTOO)

The forward P/S ratio determines the market value of the business relative to projected revenue, allowing for an assessment of how efficiently expected cash flows are capitalized. By analyzing the forward P/S metric, an investor compares the sales growth rates of T2 Biosystems, Inc. (TTOO) with its market valuation, which directly depends on the scaling of T2Dx systems in clinics and the expansion of the list of FDA-approved tests for sepsis diagnostics.

Key competitors

Forward P/S Multiple ABT (Abbott)|Thermo Fisher Scientific Inc. (TMO) - Market Cap to Future Revenue Ratio|GE Healthcare Corp - Forward P/S Multiple|MTD (Mettler Toledo Inc) - Market Cap to Projected Revenue|WAT: Forward P/S Multiple|TECH - Market Cap to Expected Sales Ratio|BRKR (Bruker) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Azenta Inc (AZTA)|Forward P/S Multiple VREX|Forward P/S Multiple Semler (SMLR)|Price-to-Projected Revenue Ratio Butterfly Network, Inc. BFLY|mesalabs.com - Price-to-Projected Revenue Ratio|QSI: Forward Price-to-Revenue Multiple|Forward Price to Sales NNOX (Nano-X Imaging)|QTRX: Forward P/S Multiple|Market Cap to Future Revenue Ratio 908 Devices Corporation (MASS)|Price-to-Projected Revenue Ratio CapsoVision, Inc.|MXCT - Projected Price to Revenue|Forward Price-to-Revenue Multiple RPID (Rapid Micro Biosystems)|Forward P/S Multiple Seer Inc (SEER)|Forward P/S Multiple HYPR (Hyperfine Corp)|Market Cap to Expected Sales Ratio FONAR Corporation Inc (FONR)|DXR - Price-to-Projected Revenue Ratio|Future Price to Revenue MDAI|VivoSim Labs Inc (VIVS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Aclarion Inc|AKYA (Akoya Biosciences Inc) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Cesca Therapeutics THMO|Price-to-Projected Revenue Ratio Talis Biomedical (TLIS)